SiBone (NASDAQ:SIBN) Insider Anshul Maheshwari Sells 11,636 Shares of Stock

SiBone (NASDAQ:SIBN) insider Anshul Maheshwari sold 11,636 shares of SiBone stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $20.11, for a total transaction of $233,999.96. Following the completion of the sale, the insider owned 223,284 shares of the company’s stock, valued at $4,490,241.24. This represents a 4.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Anshul Maheshwari also recently made the following trade(s):

• On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total transaction of $224,784.56.
• On Wednesday, August 19th, Anshul Maheshwari sold 5,747 shares of SiBone stock. The stock was sold at an average price of $19.55, for a total transaction of $112,353.85.
• On Monday, August 17th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The shares were sold at an average price of $18.65, for a total transaction of $87,002.25.
• On Thursday, July 2nd, Anshul Maheshwari sold 3,317 shares of SiBone stock. The stock was sold at an average price of $16.77, for a total value of $55,626.09.

SiBone Stock Performance

Shares of SIBN opened at $19.43 on Thursday. The firm has a market capitalization of $861.70 million, a P/E ratio of -57.15 and a beta of 0.66. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 7.55. SiBone has a one year low of $11.48 and a one year high of $21.89. The business has a fifty day moving average of $17.74 and a 200 day moving average of $15.40.

SiBone (NASDAQ:SIBN) last announced its earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.06. The business had revenue of $56.01 million for the quarter, compared to analysts’ expectations of $55.34 million. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. As a group, sell-side analysts anticipate that SiBone will post -0.4 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. UBS Group raised their price objective on shares of SiBone from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Weiss Ratings raised SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 20th. Truist Financial reaffirmed a “buy” rating and issued a $23.00 price objective (up from $21.00) on shares of SiBone in a research note on Tuesday, August 4th. Finally, TD Cowen increased their target price on SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, SiBone has a consensus rating of “Moderate Buy” and an average target price of $24.17.

Institutional Investors Weigh In On SiBone

Large investors have recently made changes to their positions in the company. Hussman Strategic Advisors Inc. bought a new stake in SiBone in the fourth quarter worth $1,656,000. UBS Group AG increased its position in SiBone by 570.2% during the fourth quarter. UBS Group AG now owns 104,731 shares of the company’s stock valued at $2,065,000 after acquiring an additional 89,105 shares during the last quarter. Dimensional Fund Advisors LP increased its position in SiBone by 41.8% during the first quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company’s stock valued at $7,816,000 after acquiring an additional 182,465 shares during the last quarter. Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of SiBone in the fourth quarter valued at $838,000. Finally, HighMark Wealth Management LLC raised its stake in shares of SiBone by 549.7% in the fourth quarter. HighMark Wealth Management LLC now owns 159,832 shares of the company’s stock valued at $3,152,000 after acquiring an additional 135,232 shares during the period. 98.11% of the stock is owned by institutional investors.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.